Testing tiespectus against aflibercept in people with wet age-related macular degeneration
Compares tiespectus with aflibercept in people with wet age-related macular degeneration.
Plain-language title generated from the registry record
Registry title: A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Key facts
- Where
- Udine, ItalySee the site
- Phase
- Phase 2/3
Where in Italy
- Presidio Ospedaliero Universitario "Santa Maria della Misericordia" Clinica Oculistica - Padiglione 7 - Piano 3Udine, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- EyeBiotech Ltd.
- Trial code
- NCT07496567
- Record updated
- 6 August 2026
- Original description
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Read full original descriptionShow less
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).
Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.
The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
The main inclusion criteria include but are not limited to the following:; Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye); The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment; The main exclusion criteria include but are not limited to the following; Has uncontrolled blood pressure at screening; History of any prior macular laser photocoagulation in the study eye; History of uveitis in either eye; History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study; Has uncontrolled glaucoma in the study eye; Active retinal disease other than the condition under investigation in the study eye; Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye.